Cardiovascular Complications of COVID-19, 1st ed. 2022 Acute and Long-Term Impacts Contemporary Cardiology Series
Coordonnateur : Banach Maciej
I. Introduction
1. Biology of SARS-CoV-2 coronavirus - origin, structure, and variants
2. COVID-19 epidemiology and differences in incidence and mortality between countries
3. Clinical symptoms and course of COVID-19
4. Risk factors of developing COVID-19 and its severe course
5. Prognosis in COVID-19 patients - statistics, risk factors
II. Cardiovascular complications of the acute phase of COVID-19
6. Myocardial injury in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)
7. Acute coronary syndrome - destabilization of atherosclerotic plaque in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)
8. Acute vascular injury (epidemiology, influence on prognosis, pathogenesis, treatment)
9. Myocarditis in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)
10. Heart failure in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)
11. Acute circulatory failure in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)
12. Cardiomyopathy in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)
13. Arrythmias in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)
14. Thromboembolic events in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)
15. Stroke in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)
16. Pulmonary embolism after COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)
17. Cardiac complications of drugs used in COVID-19 therapy
III. Influence of the treatment of cardiovascular diseases on the course of COVID-19
18. Omega-3 acids and COVID-19 (mechanism of action, effect on prognosis)
19. Statins and COVID-19 (mechanism of action, effect on prognosis)
20. ACEI / ARB in COVID-19 (mechanism of action, effect on prognosis)
21. Colchicine in COVID-19 (mechanism of action, effect on prognosis)
22. Antiplatelets drugs (mechanism of action, effect on prognosis)
23. Other medications (mechanism of action, effect on prognosis)
IV. Cardiovascular complications of long-COVID-19
24. Long COVID-19 - definition, epidemiology, and clinical implications
25. Cardiovascular complications of Long-COVID – prevalence, diagnosis, risk factors.
26. Cardiovascular complications of Long-COVID – management.
V. The impact of the Covid-19 pandemic on the CVD diagnosis, monitoring and outcomes.
VI. The impact of the COVID-19 pandemic on e-services and digital tools development in medicine.
Prof. Maciej Banach was an Undersecretary of State at the Ministry of Science and Higher Education of the Republic of Poland (2010-2012), and a President of the Polish Mother's Memorial Hospital - Research Institute (PMMHRI) (2014-2021). He is a Head of Cardiovascular Research Centre at University of Zielona Gora, full Professor of Cardiology at the Medical University of Lodz (MUL) and PMMHRI, Head of Department of Preventive Cardiology and Lipidology at the Medical University of Lodz (MUL), Poland.
He is a Secretary of the European Atherosclerosis Society (EAS) (2021-2024) and member of the Scientific and Health Policy Advisory Group of the FH Europe. He is a Founder and Head of the Polish Lipid Association (PoLA) (2011-) and Lodz Chapter of Polish Society of Hypertension (2009-). He is the founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2012-) – a group of over 150 worldwide experts aimed to investigate the most important issues in the field of lipid disorders, hypertension, nutrition and cardiovascular risk, as well as the President of the International Lipid Expert Panel (ILEP; ilep.eu) (2015-), currently with >100 recognized worldwide experts, which has been founded to prepare recommendations in the area of preventive cardiology, atherosclerosis and natural products in the most debatable issues that have not been covered in the existing guidelines. He is also a member of the REPROGRAM and CAPISCO Consortia – a group of experts challenging with Covid-19 pandemic, member of 2 largest worldwide databases – the Global Burden of Disease (GDB) (IHME, University of Washington, Seattle, US) and Non-Communicable Diseases Risk Factor Collaboration (NCD-RisC, Imperial College of London, UK). He is also Founder and President of the foundation – Think-Tank “Innovation for Health”, which gathers six main health research institutes and over 40 medical business representatives in Poland with
Provides a contemporary perspective on the emerging links between COVID-19 and cardiovascular disease
The first comprehensive approach on COVID-19 cardiac complications
Offers clear recommendations on how to manage and avoid the increased number of COVID-19 related deaths
Date de parution : 12-2023
Ouvrage de 437 p.
15.5x23.5 cm
Date de parution : 12-2022
Ouvrage de 437 p.
15.5x23.5 cm
Thème de Cardiovascular Complications of COVID-19 :
Mots-clés :
COVID-19 and Cardiology; Cardiac Complications of COVID-19; Cardiovascular System in COVID-19; Long COVID-19; Cardiology and Long-COVID-19; Cardiovascular complications of Long-COVID; Cardiomyopathy in COVID-19; Stroke in COVID-19; Pulmonary embolism after COVID-19; Cardiac complications of drugs used in COVID-19 therapy; The impact of the Covid-19 pandemic on the CVD diagnosis; The impact of the COVID-19 pandemic on e-services